Suppr超能文献

台湾地区儿童接种甲型 H1N1 流感疫苗后,先前感染和重复接种对抗体滴度的影响:对公共卫生的启示。

Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.

机构信息

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University (NTU), Taipei 100, Taiwan, ROC.

Department of Pediatrics, NTU Hospital and NTU College of Medicine, Taipei 100, Taiwan, ROC.

出版信息

Vaccine. 2022 May 26;40(24):3402-3411. doi: 10.1016/j.vaccine.2022.03.047. Epub 2022 May 4.

Abstract

BACKGROUND

The objective of this study was to evaluate the effects of prior-infection and repeated vaccination on post-vaccination antibody titers.

METHODS

A(H1N1)pdm09 strain was included in 2009 pandemic monovalent, 2010-2011, and 2011-2012 trivalent influenza vaccines (MIVpdm09, TIV10/11, TIV11/12) in Taiwan. During the 2011-2012 influenza season, we conducted a prospective sero-epidemiological cohort study among schoolchildren from grades 1 - 6 in the two elementary schools in Taipei with documented A(H1N1)pdm09 vaccination records since 2009. Serum samples were collected at pre-vaccination, 1-month, and 4-months post-vaccination (T1, T2, T3). Anti-A(H1N1)pdm09 hemagglutination inhibition titers (HI-Ab-titers) were examined. We also investigated the impact of four vaccination histories [(1) no previous vaccination (None), (2) vaccinated in 2009-2010 season (09v), (3) vaccinated in 2010-2011 season (10v), and (4) vaccinated consecutively in 2009-2010 and 2010-2011 seasons (09v + 10v)] and pre-vaccination HI-Ab levels on post-vaccination HI-Ab responses as well as adjusted vaccine effectiveness (aVE) against serologically-defined infection from T2 to T3.

RESULTS

TIV11/12 had zero serious adverse events reported. A(H1N1)pdm09 strain in TIV11/12 elicited seroprotective Ab-titers in 98% of children and showed promising protection (aVE: 70.3% [95% confidence interval (CI): 51.0-82.1%]). Previously unvaccinated but infected children had a 3.96 times higher T2 geometric mean titer (T2-GMT) of HI-Ab than those naïve to A(H1N1)pdm09 (GMT [95% CI]: 1039.7[585.3-1845.9] vs. 262.5[65.9-1045], p = 0.046). Previously vaccinated children with seroprotective T1-Ab-titers had a higher T2-GMT and a greater aVE than those with non-seroprotective T1-Ab-titers. Repeatedly vaccinated children had lower T2-GMT than those receiving primary doses of TIV11/12. However, after controlling prior infection and T1-Ab-titers, differences in T2-GMT among the four vaccination histories became insignificant (p = 0.16).

CONCLUSION

This study supports the implementation of annual mass-vaccination with A(H1N1)pdm09 in schoolchildren for three consecutive influenza seasons when vaccine and circulating strains were well matched, and found that prior infection and pre-vaccination HI-Ab levels positively impacted post-vaccination HI-Ab responses.

摘要

背景

本研究旨在评估既往感染和重复接种对疫苗接种后抗体滴度的影响。

方法

在台湾,A(H1N1)pdm09 株被纳入 2009 年大流行单价疫苗、2010-2011 年和 2011-2012 年三价流感疫苗(MIVpdm09、TIV10/11、TIV11/12)中。在 2011-2012 年流感季节,我们对台北两所小学一至六年级有记录的 A(H1N1)pdm09 疫苗接种史的学生进行了前瞻性血清流行病学队列研究。在接种前、接种后 1 个月和 4 个月(T1、T2、T3)采集血清样本。检测抗 A(H1N1)pdm09 血凝抑制抗体滴度(HI-Ab-titers)。我们还研究了四种接种史[(1)无既往接种史(None),(2)2009-2010 年接种(09v),(3)2010-2011 年接种(10v),和(4)连续 2009-2010 年和 2010-2011 年接种(09v+10v)]和接种前 HI-Ab 水平对疫苗接种后 HI-Ab 反应的影响,以及从 T2 到 T3 的血清学定义感染的调整疫苗有效性(aVE)。

结果

TIV11/12 报告无严重不良事件。TIV11/12 中 A(H1N1)pdm09 株诱导 98%儿童产生血清保护性 Ab 滴度,显示出良好的保护效果(aVE:70.3%[95%置信区间(CI):51.0-82.1%])。既往未接种但感染过的儿童 T2 几何平均滴度(T2-GMT)比未感染过 A(H1N1)pdm09 的儿童高 3.96 倍(GMT[95%CI]:1039.7[585.3-1845.9]比 262.5[65.9-1045],p=0.046)。既往接种过且 T1-Ab 滴度具有保护作用的儿童 T2-GMT 较高,aVE 也较高。重复接种的儿童 T2-GMT 低于接受 TIV11/12 初免剂量的儿童。然而,在控制既往感染和 T1-Ab 滴度后,四种接种史之间 T2-GMT 的差异变得无统计学意义(p=0.16)。

结论

本研究支持在疫苗和流行株匹配良好的情况下,对学龄儿童连续三个流感季节进行 A(H1N1)pdm09 年度大规模疫苗接种,并且发现既往感染和接种前 HI-Ab 水平对疫苗接种后 HI-Ab 反应有积极影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验